Page 6 - Project Twenty News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Psychopharmacology. The project, poised to provide patients access to affordable medical cannabis treatment, was launched in 2019 at the Royal College of Psychiatrists in London. The UK's national medical cannabis registry is monitored by an independent scientific body, Drug Science. Vertically integrated CPG cannabis company Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX:KHRNF) was the first supplier of EU-GMP high-THC dried cannabis flower to Project Twenty 21's findings. Khiron, which has core operations in Latin America, is a founding member of Project Twenty 21. Project Twenty 21's Fin...

Amanita Muscaria is an understudied species of psychoactive mushroom that’s as commonplace as it is misunderstood. The iconic red-capped, white-dotted toadstool represents the archetypal idea of a mushroom in most people’s minds, yet few are aware of its therapeutic potential as a... Read More... Don't Miss Any Updates! News Directly in Your Inbox Subscribe to:

(1) Khiron is a founding member of Project Twenty 21 and was the first supplier of EU-GMP high-THC dried cannabis flower to the study The findings show that medical Cannabis dramatically improves quality of life for people with life-limiting conditions, including Chronic Pain, Multiple Sclerosis, Tourette's Syndrome and PTSD Legal prescriptions allow patients to access medical cannabis without engaging in criminality and to avoid dependency associated with other medicines commonly prescribed for these debilitating conditions TORONTO, May 11, 2021 /PRNewswire/ -- Khiron Life Sciences Corp. (...

Khiron Receives Accreditation for UK Medical Cannabis Education and Partners with UK's Cellen Therapeutics to Improve Clinician Education USA - English Share this article Share this article UK medical professionals may now earn CPD credits through Khiron's medical cannabis education program The Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK, to increase patient access via medical cannabis education As a leading international medical cannabis educator, nearly 1,000 medical professionals in Latin America and the United Kingd...

Why the Kanabo share price is up 20% today More on: The Kanabo Group (LSE: KNB) share price is up 32%, at the time of writing. The gain came after the medical cannabis group announced a new production agreement. Kanabo will partner with Polish firm PharmaCann Polska. The two companies will produce medicinal cannabis formulations for Kanabo’s VapePod device. US$12.3 TRILLION out of thin air… And if you click here we’ll show you something that could be key to unlocking 5G’s full potential... It’s been a rollercoaster ride for shareholders who bought into the business when the stock ...